Stay updated on RGX-111 Gene Therapy in MPS I Clinical Trial
Sign up to get notified when there's something new on the RGX-111 Gene Therapy in MPS I Clinical Trial page.
Latest updates to the RGX-111 Gene Therapy in MPS I Clinical Trial page
- Check3 days agoChange DetectedAdded glossary terms: Mucopolysaccharidosis, MPS-I-H/S and Mucopolysaccharidosis type 1, expanding disease terminology related to the study.SummaryDifference0.1%
- Check10 days agoChange Detected- Hurler-Scheie Syndrome was removed from the list of conditions on the study page. This updates the documented scope of conditions associated with the study.SummaryDifference0.1%
- Check17 days agoChange DetectedThe page notes a FDA clinical hold on RGX-111 due to a safety concern and expands the study details with design, enrollment, locations, eligibility criteria, and pharmacodynamic and safety endpoints.SummaryDifference7%
- Check25 days agoChange Detected- Site framework updated to v3.4.3. No visible changes to the study details or navigation.SummaryDifference0.1%
- Check53 days agoChange DetectedRevision: v3.4.2 was added and the government funding lapse notice (and Revision: v3.4.1) was removed; these changes do not affect the study data, eligibility criteria, or other core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check60 days agoChange DetectedA government funding status notice appears at the top of the page, and the site version updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
Stay in the know with updates to RGX-111 Gene Therapy in MPS I Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RGX-111 Gene Therapy in MPS I Clinical Trial page.